Alexion Pharmaceuticals Inc

Find Ratings Reports
ALXN : NASDAQ : Health Care
$127.22 | %
Today's Range: 127.18 - 132.30
Avg. Daily Volume: 1,622,200
09/23/16 - 4:00 PM ET

Financial Analysis


ALEXION PHARMACEUTICALS INC's gross profit margin for the second quarter of its fiscal year 2016 is essentially unchanged when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. ALEXION PHARMACEUTICALS INC is extremely liquid. Currently, the Quick Ratio is 2.72 which clearly shows the ability to cover any short-term cash needs. ALXN managed to increase the liquidity from the same period a year ago, despite already having very strong liquidity to begin with. This would indicate improved cash flow.

During the same period, stockholders' equity ("net worth") has remained virtually unchanged only decreasing by 4.13% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q2 FY16 Q2 FY15
Net Sales ($mil)753.12636.21
EBITDA ($mil)300.44243.69
EBIT ($mil)202.65231.13
Net Income ($mil)114.94170.22


Balance Sheet Q2 FY16 Q2 FY15
Cash & Equiv. ($mil)1180.051494.35
Total Assets ($mil)13029.3513167.72
Total Debt ($mil)3446.673629.56
Equity ($mil)8199.348552.87


Profitability Q2 FY16 Q2 FY15
Gross Profit Margin94.4893.8
EBITDA Margin39.8938.3
Operating Margin26.9136.33
Sales Turnover0.220.18
Return on Assets0.694.5
Return on Equity1.096.92
Debt Q2 FY16 Q2 FY15
Current Ratio3.593.29
Debt/Capital0.30.3
Interest Expense23.793.97
Interest Coverage8.5258.2


Share Data Q2 FY16 Q2 FY15
Shares outstanding (mil)224.22226.02
Div / share0.00.0
EPS0.510.83
Book value / share36.5737.84
Institutional Own % n/a n/a
Avg Daily Volume1831465.01588731.0

Valuation


HOLD. ALEXION PHARMACEUTICALS INC's P/E ratio indicates a significant premium compared to an average of 42.78 for the Biotechnology industry and a significant premium compared to the S&P 500 average of 24.84. Conducting a second comparison, its price-to-book ratio of 3.55 indicates a premium versus the S&P 500 average of 2.78 and a significant discount versus the industry average of 10.46. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
ALXN 324.25 Peers 42.78   ALXN 35.31 Peers 21.27

Premium. A higher P/E ratio than its peers can signify a more expensive stock or higher growth expectations.

ALXN is trading at a significant premium to its peers.

 

Premium. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

ALXN is trading at a significant premium to its peers.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
ALXN 21.84 Peers 31.52   ALXN 0.55 Peers 0.49

Discount. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth expectations.

ALXN is trading at a discount to its peers.

 

Premium. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

ALXN trades at a premium to its peers.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
ALXN 3.55 Peers 10.46   ALXN -86.31 Peers 1.93

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

ALXN is trading at a significant discount to its peers.

 

Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

However, ALXN is expected to significantly trail its peers on the basis of its earnings growth rate.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
ALXN 10.31 Peers 690.55   ALXN 18.00 Peers 51.56

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

ALXN is trading at a significant discount to its industry on this measurement.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

ALXN significantly trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades